HedgePath Pharmaceuticals Announces Name Change to INHIBITOR Therapeutics, Inc. and Ticker Symbol Change to "INTI" Effective August 20, 2019

Author's Avatar
Aug 20, 2019
Article's Main Image

New Corporate Brand Exemplifies Multiple Near-term Growth Opportunities Involving Lead Technology, SUBA™-Itraconazole, Inhibiting the Hedgehog Signaling Pathway

INHIBITOR to Hold End of Phase 2 Meeting with FDA in Q4 2019 Prior to Filing IND for Phase 2b Clinical Trial of SUBA-Itraconazole in Prostate Cancer

INHIBITOR Renews and Expands Exclusive Worldwide Option Agreement with the University of Connecticut for Novel Compounds that Inhibit Upstream Targets of the Hedgehog Pathway

PR Newswire